Journal of Physical, Biomedical and Biological Sciences
eISSN: 3005-6489
www.jpbab.com
*J. Phys. Biomed. Biol. Sci., 2024; Volume, **3**: 33*

Review Article **Open Access**

CLASSIFICATION, PREVALENCE AND TREATMENT OF HEPACVIRIUS C

HASSAN HAU[1], RIASAT A[2], ZIA T[3], ISHAQ S[4], ULLAH A[5*]

[1]*Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan*
[2]*School of Allied Health and Social Care, Anglia* Ruskin University *(ARU), East Anglia, United Kingdom*
[3]*Cell Development and Microbiology, Department of Biological Sciences, Ohio University, Athens OH, United States of America*
[4]*Department of Biomedical Engineering (Medicine), Guangdong Provincial Key Laboratory of System Biology and Synthetics Biology for Urogenital Tumors, Shenzhen University (SZU), Guangdong, China*
[5]*Institute of Translational Pathology, University Hospital Cologne, Cologne, Germany*
**Correspondence author email address: aminbiotech7@gmail.com*

(Received, 19th September 2022, Revised 22nd October 2024, Published 27th October 2024)

Abstract *Hepacivirus C has been remembered for the Flaviviridae family. It encompasses positive sense RNA infection and an individual from the Hepacivirus species. It's the overall issue and its predominance differs throughout the world while the greater part was in the USA however, now Egypt is the most influenced one. Its genotype varies because of the higher rate of recombination in the RNA genome. HCV significant transmission occurs due to blood transfusion. It can cause exhaustion, jaundice, anorexia, and numerous different diseases. It likewise impacts the liver if it's in a persistent structure. Genotypes and subtypes are 8 and numerous (to be exact right around 126) individually. Genotype 1 has the most significant rate around the planet which influences around 40-80% of the population. USA has the most significant level of 1a and 1b, while in different nations genotype 1a isn't so normal. Pakistan has the most elevated level of HCV genotype 3a. Medicines have been built up that incorporate DAA (direct-acting antivirals), IFN-α (interferon alpha) Ribavirin, etc. A profoundly viable treatment is DAA. It may be utilized for the treatment of all age patients and the most elevated adequacy rate has been seen in youngsters because of DAA treatment. Interferon is given in a mix with other drugs. In recent years, practically half of the ongoing HCV-tainted patients have been restored with treatment other than DAA which includes ribavirin and interferon.*

Keywords*:* *Hepacivirus C; Flaviviridae family; RNA infection; HCV; IFN-α*

Introduction

HCV is a worldwide issue and an exceptionally basic disease, influencing 71 million individuals everywhere in the world. It can cause liver malignancy, cirrhosis, and fibrosis are additionally remembered for the issues that have been brought about by HCV. Yearly around 399,000 demise happen because of HCC and fibrosis which are the consequence of HCV (Puchades Renau and Berenguer, 2018). HCV isn't just a liver-related issue, it also causes numerous nonhepatic indications on different organs of the body, for example, skin, salivary organs, and kidneys. These problems are present in 1/3rd of HCV patients. It is available at an exceptionally high rate in Africa and Center East while the most reduced rate has been accounted for in the Americas, Australia, and North and West Europe (Hajarizadeh et al., 2013). In 2015 patient were accounted for were 1.75 million who were restricted from HCV events. It was because of the dubious signs and highlights of intense and persistent contamination that the greater part of patients enduring constant HCV were ignorant of the disease (Puchades Renau and Berenguer, 2018). HCV is transformed by blood, so is considered in the classification of blood-borne. The most widely recognized transmission pathway or course is skin percutaneous through IVDU, bonding of blood that isn't tried appropriately or its screening has not been done legitimately or because of the flightiness in avoiding potential risk in medical services units. HCV transmission could likewise happen in a sexual way that incorporates transmission to youngsters from mother notwithstanding, this method of transmission isn't pervasive and happens infrequently (Roberts and Yeung, 2002). Pakistan exclusively has 10 million patients of it (Cooke et al., 2013; Raja et al., 2008). HCC and cirrhosis event apportion in carrier patients is 75% and 25% respectively (Alter, 2007). With the assistance of DAA 90 % of patients can be dealt with it is a viable treatment somewhat for HCV. It can also be transmitted to the child from the mother (Roberts and Yeung, 2002; Terrault, 2002). HCV is from family Flaviviridae. Its properties incorporate that it is covered with lipid film, and a little and round fit as a fiddle. It has RNA for infections. Its breadth is 50nm

(Bostan and Mahmood, 2010). 9.6 kb is the length of its genome (Greten et al., 2005), and two finishes 5′ and 3′ untranslated areas (UTRs) are available (Simmonds, 2004). 5′UTR is the piece of the genome that is more preserved and helps in genotyping and transformative investigations (Fan et al., 2005)

Types of Hepacivirus C

HCV is divided into two stages which are

- Chronic Hepatitis C
- Acute Hepatitis C

Acute hepatitis C

The danger of intense HCV is higher in people who go through blood bonding, body puncturing, tattoos, or individuals who are more associated with sexual exercises (van de Laar et al., 2010). It's not as serious as the ongoing one and is habitually analyzed when contrasted with the last mentioned. Its manifestations and actual inconvenience incorporate anorexia, jaundice, or stomach distress. Actual discoveries are just in 33% of patients while in others these are pretty much as evident as in the last mentioned (Alric et al., 1997).

Chronic Hepatitis C

As described before liver infection and HCC are related to HCV in Western nations. Continuously irritation is caused because of HCV further reason for cirrhosis between the period of 20-30 years of HCV disease. As indicated by some examinations from the last 22 years its rate has been delayed down to 2-3% while increment to 51% (Tong et al., 1995). The fibrosis movement is also brought about by its 20 years of contamination. Patients languishing. The pace of fibrosis is 41% which is multiple times more in patients experiencing HCV 30 years (Thein et al., 2008). Constant hepatitis is additionally related to numerous different illnesses which are as per the following which are Non hepatic sign

- HCV-related nephropathy
- Diabetes type 2
- Cerebrovascular and Heart problem (Cacoub et al., 1999)

Consolidated HBV and HCV are prevalent because of their comparable transmission mode. Commonness of it in HBsAg positive and HCV patients is 5-20% and 2-10% individually (Aghemo and Colombo, 2014). There are an absolute of 8 genotypes and more than 120 subtypes of HCV. Genotypes 1-3 are more predominant worldwide and consequently are supposed to be endemic. Genotyping plays a crucial part in the HCV treatment and fixing of HCV disease (Shekhar, 2018).

Transmission

The primary transmission courses are blood bondings, IVDU, and infusion. Different courses incorporate exchange to youngsters from mothers.

Blood bonding

Before the revelation of HCV, it was viewed that the vast majority of the non-A, non-B hepatic contaminations spread because of the microorganism that has some popular qualities or properties. HCV was viewed as the most crucial wellspring of blood-borne disease. It was done after the HBV ID and HBsAg benefactor usage screening in the 1970s (Prati, 2006). HCV transmission happens by blood move however with additionally related blood items (Kenny-Walsh, 1999). During 2002 the danger of post-bonding HCV decreased to 1 from 7.7% in 276,000 gifts in the USA, while in Italy it was diminished to 1% from 3.5%. It was because of the utilization of the test for blood screening givers (Velati et al., 2002). Blood screening isn't controlled in the low-pay nations appropriately when contrasted with the created or rich nations (Tagny et al., 2008). As per the WHO Worldwide Data Set Blood Wellbeing Report in 2011, over 25% of blood supply is gathered or acquired from volunteers who are blood benefactors, while blood gifts in 39 nations are tried consistently for irresistible specialists, including HCV. It was led in 40 nations (Report, 2011), and Ill-advised quality control methods and utilization of examination testing quickly bring about bringing down the affectability that identifies the diseases. A global report that was led or gathered from 17 African nations demonstrated that HCV sensitivities are as low as 80%, while for HIV and HBsAg it was 81.4% and 75.6% separately (Laperche and Transfusion, 2013).

Latrogenic

After the second universal battle, with the expanding no of individuals utilizing infusions and blood bonding, there was a horrible expansion in HCV genotype 1b around the world. Its occurrence was explicitly in the medication clients (Magiorkinis et al., 2009) from the previous long-term study it was seen that after episodes by endoscopy or myocardial perfusion, needles are the wellspring of transmission, not the system (Gutelius et al., 2010; Patel et al., 2006). Albeit in Created and industrialized nations, the pace of HCV transmission through this course is diminished however balance should be made in the control of contamination and hygiene else it will require some investment to reoccur (Thompson et al., 2009). In immature or asset-restricted areas this wellspring of transmission of HCV assumes an imperative part in episodes of plague. Egypt is on top of the rundown that shows the Most elevated pace of HCV in the 15-59 years of age patients Egypt is on the first spot on that list. It represents 14.7 % (Guerra et al., 2012).

Infusion drug use

Around 6 million people groups are enjoying infusion drug utilization which is the reason it is the fundamental method of causing HCV. It has been turning into a significant transmission course that causes contamination due to the iatrogenic transmission decay alongside benefactor screening execution and strategies for disease control. This wellspring of transmission is additionally in asset-restricted nations (Jimenez et al., 2010; Quan et al., 2009). Different advances, techniques, or acts could

be taken to dodge or decrease HCV transmission from infusion drug use. These means are supposed to be well-being mediations. These incorporate those that focus on

- Change in conduct,
- Disinfecting of needles

Sedative replacement programs reduce the utilization of medications that are unsafe for well-being and help in advancing protected strategies. It decreased the HCV transmission up to 30-65% (Turner et al., 2011).

Residual courses

Transmission of HCV has additionally been identified with tattoos, utilization of needles, and infusions inappropriately unhygienicly. Scarification is additionally viewed as a method of transmission, yet confirmations for this are inadequate and lacking. There are likewise some cryptogenic ways that imply dubious ways for HCV transmission. Transmission may likewise prompt the way toward causing contamination without seroconversion

Courses on Transmission of HCV in Pakistan

The appearance of indications could be in the middle of 14 days to 180 days in the wake of getting tainted with infection. Jaundice, weakness, and stomach torment are remembered for it. There are different courses of transmission in Pakistan patients. A large portion of the transmission is because of the bonding of blood by tainted needles.

Table 1 Routes of transmission percentage of* Hepacivirus C *in Pakistan (*Nouroz et al., 2015*)

Route **Treatment related to tooth**	**%age** **1.6**
Injection	60
Blood transfer	10
Tattoo making	46.3
Piercing	30.1
Needle stick	2
Sexual	15
Nail trimming	24.3
Shaving	14.5
Surgeries	7.6

Hepacivirus c correlation with hepatocellular carcinoma

Hepatocellular carcinoma (HCC) causes liver malignancy for roughly 85-90%. It is the liver malignant growth that is gotten from hepatocytes It is present in the two People around the world. It is discovered to be at fifth situation in like manner malignant growth in men, while among women it is at position 7 among the most well-known cancers (Cancer, 2012). It is at the no. 3 that cause passing identified with, lungs and stomach disease are the excess two that surpass it. It isn't in the rundown of most regular disease on the planet however the individual experiencing it has less endurance time, and likewise has high mortality because of which it is viewed as the overall weight. Its death rate is 0.95, while its endurance rate is 6.9% for a very long time. The explanation is that fewer patients are analyzed at the beginning phase. The time frame for the middle endurance is 330 days (Greten et al., 2005). HCV and HBV both are liable for HCC events with a record of 10-20% and 75%-80% separately. Up to 70% of the licenses of HCC show the occurrence of hostile to HCV immune response in their serum. This was in the zones where the frequency pace of HCC is very low, for example, Western Europe and North America demonstrating HCV as the major etiological factor (Colombo et al., 1989). Pathways for the main consideration or causative specialist of HCC Hepacivirus C infection are roundabout, for example, persistent aggravation, cell passings, and expansion. Constant liver infection is likewise answerable for HCC because it can cause fibrosis and afterward ultimately cirrhosis. Host and the climate additionally assume a significant part in the cirrhosis movement. These are more urgent than the viral variables. These variables incorporate more seasoned age, male sex, >50g admission of liquor each day (Altekruse et al., 2014)

Frequency of HCV-related HCC

HCV-causing HCC is related to fibrosis arrangement. 2-6% is the event among the patients of HCV cirrhosis causing HCC yearly. Danger of HCC among HCV patients increment to 15–20 overlap as contrasted and HCV negative patients (Mahale et al., 2017). The odds of HCC in patients who experience the ill effects of HCV constant contamination for a very long time is 1-3%. Joined disease of HBV HCV causing HCC rate is higher than creating contamination because of alone HCV and HBV. Liquor utilization is the central point causing HCC in the Western world (Mancebo et al., 2013). Generally o HCV-HCC is related to cirrhosis and fibrosis of the liver (Finkelmeier et al., 2018). After the foundation of cirrhosis event pace of liver malignant growth is 3.5% each year. The Pace of HCC in HCV-tainted patients improves up to 15-20 folds, with a frequency pace of 15 to 20 overlays yearly (Lok et al., 2009). HCV was the significant reason for 170000 new malignant growth cases in 2012 (Brookman-May et al., 2017) Demise rate because of HCV causing HCC has been increment up to 21.1% (Wang et al., 2016). HCV-related HCC event changes with the geological area just as with culture. It's the significant explanation of HCC in America, Europe, Japan, and South America, while (HBV) is the explanation of HCC in Asia and Africa (Yang and Roberts, 2010) Practically 2.5% populace around the globe is influenced by HCV (Petruzziello et al., 2016). It was regular in Japan and the USA in the 1920s and 1960s. Individuals influenced with HCV and HCV-related HCV in Japan are assessed to be 2.5% and 85% respectively (Sievert et al., 2011). On the opposite USA has less level of HCV and HCV-related HCC that reaches 1.8% and 50-60% separately (Altekruse et al., 2014).

Danger factors for HCC improvement because of ongoing HCV contamination Factors other than HCV for HCC incorporate

- liver sickness
- Viral genotype
- Lifestyle factors
- Obesity
- Diabetes mellitus.

HCC danger in HCV patients increases because of the combined contamination of HBV and HIV predominantly. HBV assumes the vital part in HBV-HCV contamination. Individuals that have undetected HBV DNA have an equivalent possibility of HCC in examination with individuals enduring exclusively with HCV (Kruse et al., 2014). While patients with dynamic HBV replication have a twofold HCC-creating hazard. There is also a 21 % increment in the death rate in correlation with inert HBV and HCV. Extensive expansion in HCC commonness in HIV-HCV patients contrasted with HCV patients has been noticed. In such a sort of populace, HCC happens at an early age (Kramer et al., 2015). Liquor and HCV have a synergetic impact on HCC. While those who devour liquor surpassing 60g in a day have twofold the danger of HCC (Hagström, 2017).

HCV movement to HCC

Viral-initiated elements and safe reactions intervene in HCV carcinogenesis. Perceptions show that center protein starts the lipogenesis and digestion of stress (Huang et al., 2007). Viral proteins of HCV straightforwardly upon cells flagging pathway that advance the HCC by halting tumor stifling qualities or because of sign pathways enactment that helps in the development and division upregulation (Okuda et al., 2002). The retinoblastoma protein and p53 tumor silencer are explicit qualities that stifle tumors quelled by the HCV center protein. Carcinogenesis is brought about by the loss of above-notch tumor-smothering qualities. The loss of these two is a synergetic influence (Shimakami et al., 2012). Improvement and advancement of HCC and fibrosis is the duty of HCV nonstructural proteins. Acceptance of changing β factor and enactment of Hepatic stellate cells (Schulze-Krebs et al., 2005). IFNs, tumor corruption factor, and persistent aggravation help in the assertion of immunologic reaction incited by the host to HCV. Aggregation of different mutational changes causes redundancy of cell cycles. These changes in aggregation additionally bring about the change of hepatocytes to Dangerous cells (Tomasetti et al., 2017).



Figure 1. HCV progression To HCV (Vescovo et al., 2016)

Structural organization of HCV genome

It is the round, little in size RNA infection that has a place with flaviriade. It was found by the presence of its serum in non a or b hepatic patients (Colombo et al., 1989). The affirmation of its reality was finished by Feinstone et al in 1975 (Feinstone et al., 1975). He found that a large portion of the hepatic patients don't have a place with HAV or HBV (Choo et al., 1989). It has been raised from tenth to the seventh position from 1990 to 2013 for the most elevated death rate

among other diseases, for example, HBV, HAV, and intestinal sickness just as tuberculosis (Stanaway et al., 2016). HCV has a genome length of 9.6Kb with single ORF and 5′ and 3 UTR locale at both edges (Margraf et al., 2004). There are 10 proteins present in the open edge district E1, E2, P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B these are called Center (c). From proteins present in center 3 are underlying and 7 Nonstructural proteins (Scheel and Rice, 2013). It is a wrapped infection

Underlying proteins

The following are remembered for these

- Protein center
- Wrapped protein
- P7 protein

Protein center

HCV protein centers have 191 amino acids in their design and are answerable for the gathering of nucleocapsid. The protein center is isolated into three areas which have the following succession of amino acids

- Area I have 1-117
- Area II has 118-174
- Area III has 175-191.

The amino acids in these areas are exceptionally hydrophobic (Boulant et al., 2005; Margraf et al., 2004). It assumes an essential part in communications with pathways related to viral life cycle and viral capsid development (McLauchlan, 2000).

Encompassed protein

E1 and E2 are the components of the passage in the cell (Krekulova et al., 2006). These recognize the cell layer receptors and afterward, permit the cell passage (De Francesco et al., 2003). E2 starts the viral connection measure being answerable for causing contamination (Rosa et al., 1996). HVR1 and HVR2 are the destinations or locales of E2 protein and killing antibodies are being focused by the E2 protein. HVR1 permits the infection to enter the Safe framework and leads to persistent disease.

P7 Protein

63 amino acids are available in the this which is available in the center of E2 and NS2. These assume an imperative part in the infection contamination because can without much of a stretch structure particle channels (Griffin et al., 2003; Steinmann et al., 2007). Particle channel and get-togethers of infection is the duty of the P7 protein (Krekulova et al., 2006).

Non-Underlying proteins

Following are remembered for these NS2, NS3, NS4A, NS4B, NS5A, and NS5B

NS2

It is of 21-23 kDa without it the replication pattern of infection couldn't be finished (Pietschmann et al., 2006). N terminal is hydrophobic while c terminal is available in the cytoplasm itself (Grakoui et al., 1993a). Two inward signals present in it are answerable for emergency room film affiliation. These are at 839–883 and 928–960 (Santolini et al., 1995; Yamaga and Ou, 2002)

NS3

67 kDa is the size of NS3 and its n terminal is engaged with serine protease action while C terminal has helical movement. Three amino acids are liable for the synergist movement of this protein (Wölk et al., 2000).

NS4

54 amino acids are available in NS4A and it is the cofactor for NS3 protein while NS4B is 27kDa (Grakoui et al., 1993b; Lundin et al., 2006). Variety into E1 and E2 districts causes the genotypes and subtypes arrangement or distinguishing proof. Its genome is typified inside protein which is inserted in the lipid encompass in which E2 proteins are installed (Kato and genomics, 2000; Zeisel et al., 2013). It repeats in contaminated individual hepatocytes (Wieland et al., 2014) and is related to liver explicit miR-122 (Jopling et al., 2005; Scheel et al., 2008). The size of the particles created by infection is 40 nm which could be in vitro or in vivo. An electron magnifying lens was utilized to notice these particles (Calattini et al., 2015)

Life pattern of Hepacivirus C

Cycles engaged with the **life cycle**

The existence pattern of this infection isn't recognized. There are issues in starting the foundation of an in vitro model of replication just as the cells that intercede in the viral section postpone the atomic system (Maggi et al., 2017; Paul et al., 2014). The course of its virion is either as a free molecule or lipoprotein encompassing the virion. The lipoprotein that encompasses the virion is low in thickness (Andre et al., 2002). It connects the film of target cells by restricting with the receptors and makes passage by the interaction called Clathrin-intervened endocytosis. In the endocytic compartment, the viral capsid is upset delivering the genome of HCV in the cytoplasm. Genome interpretation at that point happens in harsh Endoplasmic Reticulum. Because of the interpretation 3000 amino corrosive buildup is developed which is cut thereafter by protease into 10 developed items (Gerresheim et al., 2017).

These proteins incorporate the underlying center, E1 and E2, and the accompanying nonstructural proteins: p7 viroporin, Nonstructural protein 2, Nonstructural protein 3, Nonstructural protein 4A, Nonstructural protein 4B, Nonstructural protein 5A, Nonstructural protein 5B. Get together of the produced virion is done in the Unpleasant Endoplasmic Reticulum. These are discharged by the interaction of exocytosis. Next infection Development happens. It is encircled by lipoprotein that helps in invulnerable getaway (Maggi et al., 2017; Paul et al., 2014).

Steps of viral life cycle

1. Attachment
2. Entrance
3. Uncoating
4. Translation

5. Replication
6. Assembly and development
7. Release



Figure 2 Replication cycle of Hepacivirus (Dustin et al., 2016)

Host response against HCV infection

Intrinsic invulnerability reaction

Intrinsic insusceptibility is a first line of safeguard for HCV disease (Schoggins and Rice, 2013) and it reestablishes the obtained resistant framework. Restricting of HCV RNA to retinoic corrosive inducible quality I, enacts the mitochondrial antiviral flagging (MAVS) proteins; twofold abandoned RNA than ties to Cost like receptor-3 urge motioning through TRIF. These then actuate NFκB and IRF3 movement to the core. At that point, at the Core, they energize communicating IFNs and ISGs so these can stop the viral replication. Notwithstanding the hindrance, it additionally communicates the proinflammatory cytokines and chemokines with the goal that these can actuate and enlist or draw in the invulnerable cells. HCV's NS3–4A protease split MAVS and TRIF extraordinarily with the goal that IFN enlistment could be decreased (Horner and Gale, 2013; Obaid et al., 2015). A few techniques or strategies could be utilized by HCV so the intrinsic viral response could without much of a stretch be hosed (Horner and Gale, 2013; Obaid et al., 2015). In HCV-contaminated hepatocytes, the communication of ISG and cleavage of MAVS don't the HCV to let full obliteration of the inborn insusceptibility reaction (Sheahan et al., 2014; Wieland et al., 2014).

Natural resistance reaction

Medication drug communications were available in these yet were being uprooted by new DAA which are Simeprevir, Paritaprevir, Daclatasvir, Ledipasvir, Ombitasvir, Sofosbuvir, and Dasabuvir.

Versatile insusceptibility

HCV replication and spread must be restricted by the natural antiviral reaction yet couldn't be eliminated or nullified without the activity system brute versatile insusceptible reaction. Hepatocyte cell passing happens because of the lift in transaminase levels bringing about the decrease of viral burden. Ongoing diseases generally keep going for around over a half year. The leeway or expulsion of infection precipitously is not uncommon except for it additionally doesn't return after this. For controlling or leeway of disease versatile insusceptibility quickly begins supporting the mount cells to focus on various HCV epitopes, comprehensively receptive killing antibodies (bNAbs) (Holz and Rehermann, 2015) T lymphocytes don't let the infection get away from the safe reaction by focusing on the numerous epitopes and lessening the odds of getaway (Dazert et al., 2009). Killing antibodies have a minor part in HCV treatment in people who are experiencing hypogammaglobulinemia HCV so their job to help in controlling HCV among such patients isn't so unmistakable (Semmo et al., 2006). Lymphocytes are answerable for the control of HCV in such circumstances.

Genotypes and subtypes of Hepacivirus C

HCV has different genotypes because of the variety in the genome. There are a total of 8 genotypes and just about 126 subtypes. They have hereditary fluctuation because of various topographical locales i.e every genotype is available in various districts of the world. Genotypes have been named from 1-8 while subtypes are marked as letters for instance 1a, 2b, and so on out of all the most common one is genotype 1 which is 46.2%, after that is genotype 3 which is 30.1 % while genotype 2,4 and 6 are have pervasiveness of 2.6 %.

Strains that have a place with having a place with regular subtypes vary in under fifteen percent at the nucleotide site (Smith et al., 2014). HCV event shifts on the whole areas just as vary in different networks too.

High and Low Pervasiveness Areas of Hepacivirus C

Subtypes 1a, 1b, 2a, 2b, 2c, 3a, 4a, 4d, 5a, and 6a are all around characterized and are specifically zones (Bartenschlager et al., 2013). Low-pervasiveness locales are Western Europe, Americas, and Australia. While high pervasiveness locales are African and The eastern Mediterranean (Hajarizadeh et al., 2013)

Winning HCV genotypes and subtypes in world

HCV event everywhere in the world is 2.5 percent which implies 177.5 million people groups are influenced by it (Petruzziello et al., 2016) Genotype 1 is about 46.2% which represents 83.4 million and is the most bountiful one on the planet. Its dissemination based on the spot incorporates North and West Europe, Asia, North and South America, and Australia (Lamoury et al., 2018; Petruzziello et al., 2016). HCV genotype 2 is probably going to happen in West and Focal Africa, (Karoney and Siika, 2013; Lavanchy and Infection, 2011). HCV genotype 3 is the most pervasive one after genotype 1 and records 54.3 million which is 30.1% around the planet. From the cases internationally, South Asia has 75% of this genotype (Petruzziello et al., 2016).

Genotype 4 is available in the Center East explicitly Egypt (Lavanchy and Infection, 2011). Genotype 4 is the overwhelming one in the Egyptians, especially subtype 4a believing it to be the region where the genotype is generally spread of HCV. Anyway, contemplates demonstrated that different genotypes and subtypes are additionally present in the various locales of the world demonstrating that HCV genotypes are available in different areas of the world (Lavanchy and Infection, 2011). Genotype 5 is exclusively in South Africa (Karoney and Siika, 2013; Lamoury et al., 2018). Genotype 6 is broadly spread in Southeast Asia, especially in Hong Kong (Lamoury et al., 2018; Lavanchy and Infection, 2011). Genotypes 2, 4, and 6 are the genotypes that represent the greater part of the leftover cases assessed to be 16.5 million which represents 9.1%, 15.0 million which represents 8.3%, and 9.8 million which represents 5.4% cases, individually. Genotype 7 was unique in one patient who was available in Canada and was an outsider (Murphy et al., 2007).

Commonness in Pakistan

In Pakistan populace contaminated with HCV is appx. 6%. The genotype that is generally common in nations is 3a. The significant reason for the spreading of HCV is the absence of treatment and mindfulness which has been spreading in the country for the most recent couple of years (Fusaro et al., 2011; Hajarizadeh et al., 2013). With genotype 3a different genotypes do likewise exist in the various regions of the country and are expanding day by day. Genotype 2a is especially in KPK (Khan et al., 2014). In 2010 Pakistan endured a catastrophic event that was flood. These likewise influence the occurrence of HCV contamination and consequently to be observed consistently and appropriately so that the spread of infection begins lessening. In 2010 an examination was directed that demonstrated HCV pervasiveness in individuals from smack is similarly higher than recently revealed populace of a similar locale. It expanded from 2.2% to 8.8% (Ahmad et al., 2006; Rauf et al., 2011)

Different Medicines for Hepacivirus C

HCV is a worldwide issue and has been spreading everywhere in the world in recent years. With each spending year new treatments or strategies are being created for the treatment of Hepacivirus C. The two most regular treatments for the treatment are interferon-based treatments and interferon-free treatments or DAA treatments.

Interferon based treatment

Opposition against infection isn't the reason for disappointment in treatment, yet the purpose behind it is obstruction of infection in the host interferon reaction (Puchades Renau and Berenguer, 2018). Its Results are influenza-like signs typically later than taking medication, shortcomings and rest problems, skin sensitivity, windedness, and blood disorders. These also lessen the bearableness and cause sensitivity in numerous patients. Patients enduring mental problems, epilepsy, persistent illnesses, and enduring with liver sickness are not given this therapy. It likewise messes up kidney relocation beneficiaries. This treatment can go through the dismissal from cells or tissue of such patients, while the pace of infection annihilation is less. Subsequently, this treatment is dodged in such patients except if the condition is dangerous and should incorporate liver treatment (Baid et al., 2003; Marcellin, 2009). At first, it was utilized for non-A and non-B hepatitis. 6% of SVR was accomplished with this strategy which was directed threefold for 24 weeks. By dragging out the chance to 336 days or 11 months pace of SVR upgraded up to 16% (Strader and Seeff, 2012). SVR rates expanded more to 34% aster 24% yet IFN joined with RBV and it expanded more after 48 weeks. SVR rates acquired was 42%.

At the point when Stake joined with IFN was utilized in monotherapy 39% SVR rate was accomplished following 48 weeks. While Stake was when joined with RBV rate expanded to 54-56% when following 48 weeks. Genotypes 2 and 3 accomplish more noteworthy SVR rates (76%–82%), while genotypes achieved lesser SVR rates (76%–82%). This was seen when the preliminaries of Stake two genotypes were explored (AMJAD et al., 2018; Davis et al., 2003; GOHAR et al., 2023).

Four pathways have been proposed for the antiviral activity of RBV

- Suppression of HCV replication
- Inosine monophosphate dehydrogenase limitation

- Replication of infection is brought about by Mutagenesis enlistment
- Altering of invulnerable response by initiating Th1 insusceptible reaction.

It's indistinct from above which system rules (Te et al., 2007). Its portion is 1 or 1.2 g/day with a deference weight (75 kg). Rash, hack, and hemolytic iron deficiency are its results however it tends to be taken care of via cautiously changing portion. It is for the two People. It is a teratogen drug. Its associations are more uncommon with RBV (AMIN et al., 2023; Awan et al., 2024; Kokudo et al., 2019).

Interferon-free treatments or DAA

DAAs original treatment was restricted to patients that are influenced by genotypes 1 and 4. The extreme results of these medications were normal. The second era of DAAs was endorsed in 2014, which targets nonstructural proteins of HCV RNA genome. At first, sofosbuvir (SOF)was the establishment of consolidated treatment. It joined with the accompanying RBV, peg-IFN, and RBV, (SOF/SIM), (SOF/DCV), (SOF/LDV) with or without RBV. In 2015 sofosbuvir control was decreased with the revelation of Dasbuvir blend with Ombitasvir and Paritaprevir/ritonavir, with the amount of 250g, 12.5mg, and 75/50 mg. It was the blend of three medications consequently the syndication of sofosbuvir blurred. The most recent and improved mix were Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir and Sofosbuvir/Velpatasvir/Voxilaprevir

Sofosbuvir (SOF)

Sofosbuvir (SOF) treats HCV genotypes 1a, 1b, 2, 3, and 4. It is additionally important for a consolidated restorative meds antiviral treatment. Its phosphorylation is done inside the phone, after entering the infection RNA strand it closes the HCV RNA stand blend before its development (Geddawy et al., 2017; Ullah et al., 2023). SOF is an amazing obstruction boundary. After a few clinical preliminaries among patients just a single patient was demonstrating opposition (Keating and Vaidya, 2014). Its results were accounted for when these were given with IFN or when the treatment was delayed than 24 weeks. It was mixed with RBV during stage three, and unfavorable impacts were noticed, for example, weakness, cerebral pain, retching, dozing affliction, tingling, anxiety, asthenia, and d loose bowels (Geddawy et al., 2017).

Ledipasvir (LDV)

Ledipasvir (LDV) is presently accessible as a blend of ledipasvir/sofosbuvir tablet It treats 1a, 1b genotypes of Hepatitis C. Oxidative digestion happens in it by obscure component. 86% of emission is from the biliary lot, while under 1% is through pee. Half-existence of LDV is 47h. Its results incorporate loose bowels, sickness, weariness, cerebral pain, and sleep deprivation (Geddawy et al., 2017; Hassan et al., 2023; Sheema et al., 2024)

Simeprevir (SIM)

Simeprevir (SIM) adequacy has been noticed for genotypes 1a and 1b. It very well may be effortlessly endured by the patients. After its blend with RBV/IFN different results were being seen that incorporate queasiness, myalgia, rash, photosensitivity, irritation, and winded. Without IFN results detailed were sickness and migraine. The noticed results for SIM/SOF were impulsive, photosensitivity, and tingling. These were seen when joined with SIM/SOF (Keating and Vaidya, 2014)

Overview of Direct acting antiviral medication

DAAs SVR rates are more noteworthy than 90%, subsequently supporting patients for starting treatment. Anyway, inordinate utilization of DAAs brings about medication collaborations especially in patients enduring different sicknesses or under the medicine of any medications (Keating and Vaidya, 2014). Checking medication drug association is fundamental. It is done to assess the connection potential during treatment. It is essential to check these associations before treatment. It is a convoluted issue because there are many medication classes either endorsed or not and consolidated DAAs, particularly protease inhibitors. Liver treatment is a significant objective for this treatment and it is additionally the most significant point for cooperation among different medications. Direct-acting antivirals go about as protein inhibitors and just as inducers.

DAAs are endorsed to utilize as of late so the information identified with it is generally invitro while this is the restriction of it as of late. These have high SVR rates however because of medication-drug communication their adequacy could diminish or may have more results. CYP inhibitor's cooperation could expand drug fixation, and communications with CYP inducers act conversely leading to disappointment of treatment. Elements for the collaborations incorporate Patient's age, Sex, Genomics, Disease stage, and Comorbidities.

Conclusion

Hepacivirus C is the overall weight. It has been influencing the world in recent years. The pervasiveness of this has been diminishing in the created nations given their assets for the treatment treatments, while in immature and agricultural nations the proportion of the HCV is extending with every day. There are 8 subtypes and more than 100 subtypes. These are because of the genomic recombination the predominance of HCV genotypes differs due to geological districts, transformations, and contamination courses around the planet everywhere in the world. Genotyping additionally has a fundamental influence on the analysis and therapy of ongoing contamination. Likewise, liable to examine development. HCV influences the 2,5% populace of the world. The most plentiful ones are genotype 3 and genotype 3. Its pervasiveness has been expanding in the agricultural nations while its rate has been diminished in evolved nations, for example,

America. Pakistan is the second most influenced country by this infection. Genotype 3 predominance in the nation is higher than different genotypes. The most noteworthy influenced region is Sindh while Punjab is finally. HCV is additionally answerable for different liver issues, for example, fibrosis cirrhosis, and so forth Hepatocellular carcinoma is likewise connected with HCV. The event pace of HCC-HCV is higher than the ordinary HCC. Its high predominance explains that in the serum of HCC-contaminated patients, there are hostile to HCV antibodies are available. DAAs drugs altered the treatment ways for HCV treatment. There will be more medication presentations in forthcoming years. There are a few difficulties that should have been dealt with which are; opposition of genotype, reduced adequacy in cirrhotic patients, and so on.

References

Aghemo, A., and Colombo, M. J. G. (2014). Treatment of patients with dual hepatitis B and C: a step in the right direction. **63**, 380-381.

Ahmad, I., Khan, S. B., ur Rehman, H., Khan, M. H., and Anwar, S. (2006). Frequency of Hepatitis B and Hepatitis C among cataract patients.

Alric, L., Fort, M., Izopet, J., Vinel, J., Charlet, J., Selves, J., Puel, J., Pascal, J., Duffaut, M., and Abbal, M. J. G. (1997). Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. **113**, 1675-1681.

Altekruse, S. F., Henley, S. J., Cucinelli, J. E., and McGlynn, K. A. J. T. A. j. o. g. (2014). Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. **109**, 542.

Alter, M. J. J. W. j. o. g. W. (2007). Epidemiology of hepatitis C virus infection. **13**, 2436.

Amin, F., Hassan, N., Bashir, K., Khan, A., Bibi, H., Irshad, M., Khan, S., Nawaz, K., and Ullah, Z. (2023). Antimicrobial susceptibility profile of various bacteria isolated from respiratory tract infection. *Bulletin of Biological and Allied Sciences Research* **2023**, 48-48.

Amjad, N., Rehman, M., Khalid, M., and Amjad, I. (2018). Construction of the infectious molecule of beta satellite associated with ageratum yellow vein disease of ageratum conyzoides. *Bulletin of Biological and Allied Sciences Research* **2018**, 13-13.

Andre, P., Komurian-Pradel, F., Deforges, S., Perret, M., Berland, J., Sodoyer, M., Pol, S., Brechot, C., Paranhos-Baccala, G., and Lotteau, V. J. J. o. v. (2002). Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. **76**, 6919-6928.

Awan, S. J., Fatima, Z., Kamran, S., Khan, A. S., Fatima, T., Imran, S., Shabbir, M., and Nadeem, S. I. (2024). Guar gum in therapeutics: a succinct exploration. *Bulletin of Biological and Allied Sciences Research* **2024**, 60.

Baid, S., Tolkoff-Rubin, N., Saidman, S., Chung, R., Williams, W. W., Auchincloss, H., Colvin, R. B., Delmonico, F. L., Cosimi, A. B., and Pascual, M. J. A. J. o. T. (2003). Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. **3**, 74-78.

Bartenschlager, R., Lohmann, V., and Penin, F. J. N. R. M. (2013). The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. **11**, 482-496.

Bostan, N., and Mahmood, T. J. C. r. i. m. (2010). An overview about hepatitis C: a devastating virus. **36**, 91-133.

Boulant, S., Vanbelle, C., Ebel, C., Penin, F., and Lavergne, J.-P. J. J. o. v. (2005). Hepatitis C virus core protein is a dimeric alpha-helical protein exhibiting membrane protein features. **79**, 11353-11365.

Brookman-May, S. D., Rodriguez-Faba, O., Langenhuijsen, J. F., Akdogan, B., Linares, E., Minervini, A., Klatte, T., Volpe, A., Brausi, M., and Marszalek, M. J. A. i. M. O. R. (2017). Challenges, hurdles and possible approaches to improve cancer care in developing countries–A short breakdown of the status quo and future perspective. **3**, 204-212.

Cacoub, P., Poynard, T., Ghillani, P., Charlotte, F., Olivi, M., Charles Piette, J., Opolon, P. J. A., and Rheumatology, R. O. J. o. t. A. C. o. (1999). Extrahepatic manifestations of chronic hepatitis C. **42**, 2204-2212.

Calattini, S., Fusil, F., Mancip, J., Thi, V. L. D., Granier, C., Gadot, N., Scoazec, J.-Y., Zeisel, M. B., Baumert, T. F., and Lavillette, D. J. J. o. B. C. (2015). Functional and biochemical characterization of hepatitis C virus (HCV) particles produced in a humanized liver mouse model. **290**, 23173-23187.

Cancer, I. A. f. R. o. (2012). GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.

Choo, Q.-L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., and Houghton, M. J. S. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. **244**, 359-362.

Colombo, M., Choo, Q., Del Ninno, E., Dioguardi, N., Kuo, G., Donato, M., Tommasini, M., and Houghton, M. J. T. L. (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. **334**, 1006-1008.

Cooke, G., Lemoine, M., Thursz, M., Gore, C., Swan, T., Kamarulzaman, A., DuCros, P., and Ford, N. J. J. o. v. h. (2013). Viral hepatitis and the Global Burden of Disease: a need to regroup. **20**, 600-601.

Davis, G. L., Wong, J. B., McHutchison, J. G., Manns, M. P., Harvey, J., and Albrecht, J. J. H. (2003). Early virologic response to treatment with

peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. **38**, 645-652.

Dazert, E., Neumann-Haefelin, C., Bressanelli, S., Fitzmaurice, K., Kort, J., Timm, J., McKiernan, S., Kelleher, D., Gruener, N., and Tavis, J. E. J. T. J. o. c. i. (2009). Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27–restricted human immune response. **119**, 376-386.

De Francesco, R., Tomei, L., Altamura, S., Summa, V., and Migliaccio, G. J. A. r. (2003). Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. **58**, 1-16.

Dustin, L. B., Bartolini, B., Capobianchi, M. R., Pistello, M. J. C. m., and infection (2016). Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy. **22**, 826-832.

Fan, W., Zhu, W., Wei, L., Wang, Q., Yin, L., Du, S., and Zhuang, H. J. J. o. g. (2005). Nonstructural 5A gene variability of hepatitis C virus (HCV) during a 10-year follow up. **40**, 43-51.

Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J., and Holland, P. V. J. N. E. J. o. M. (1975). Transfusion-associated hepatitis not due to viral hepatitis type A or B. **292**, 767-770.

Finkelmeier, F., Dultz, G., Peiffer, K.-H., Kronenberger, B., Krauss, F., Zeuzem, S., Sarrazin, C., Vermehren, J., and Waidmann, O. J. L. C. (2018). Risk of de novo hepatocellular carcinoma after HCV treatment with direct-acting antivirals. **7**, 190-204.

Fusaro, A., Monne, I., Salviato, A., Valastro, V., Schivo, A., Amarin, N. M., Gonzalez, C., Ismail, M. M., Al-Ankari, A.-R., and Al-Blowi, M. H. J. J. o. v. (2011). Phylogeography and evolutionary history of reassortant H9N2 viruses with potential human health implications. **85**, 8413-8421.

Geddawy, A., Ibrahim, Y. F., Elbahie, N. M., and Ibrahim, M. A. J. J. o. t. i. m. (2017). Direct acting anti-hepatitis C virus drugs: clinical pharmacology and future direction. **5**, 8-17.

Gerresheim, G. K., Dünnes, N., Nieder-Röhrmann, A., Shalamova, L. A., Fricke, M., Hofacker, I., Zu Siederdissen, C. H., Marz, M., Niepmann, M. J. C., and sciences, m. l. (2017). microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3′ untranslated region: function in replication and influence of RNA secondary structure. **74**, 747-760.

Gohar, M., Rehman, I., Ahmad, J., Ahmad, F., Bashir, K., Ikram, S., Hassan, N., Khan, M., and Ullah, A. (2023). Prevalence of hepatitis b virus and genotypes in the region of khyber pakhtunkhwa Pakistan. *Bulletin of Biological and Allied Sciences Research* **2023**, 53-53.

Grakoui, A., McCourt, D., Wychowski, C., Feinstone, S., and Rice, C. J. J. o. v. (1993a). Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. **67**, 2832-2843.

Grakoui, A., McCourt, D. W., Wychowski, C., Feinstone, S. M., and Rice, C. M. J. P. o. t. N. A. o. S. (1993b). A second hepatitis C virus-encoded proteinase. **90**, 10583-10587.

Greten, T., Papendorf, F., Bleck, J., Kirchhoff, T., Wohlberedt, T., Kubicka, S., Klempnauer, J., Galanski, M., and Manns, M. J. B. j. o. c. (2005). Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. **92**, 1862-1868.

Griffin, S. D., Beales, L. P., Clarke, D. S., Worsfold, O., Evans, S. D., Jaeger, J., Harris, M. P., and Rowlands, D. J. J. F. l. (2003). The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. **535**, 34-38.

Guerra, J., Garenne, M., Mohamed, M., and Fontanet, A. J. J. o. v. h. (2012). HCV burden of infection in Egypt: results from a nationwide survey. **19**, 560-567.

Gutelius, B., Perz, J. F., Parker, M. M., Hallack, R., Stricof, R., Clement, E. J., Lin, Y., Xia, G.-L., Punsalang, A., and Eramo, A. J. G. (2010). Multiple clusters of hepatitis virus infections associated with anesthesia for outpatient endoscopy procedures. **139**, 163-170.

Hagström, H. J. C. h. r. (2017). Alcohol consumption in concomitant liver disease: how much is too much? **16**, 152-157.

Hajarizadeh, B., Grebely, J., Dore, G. J. J. N. r. G., and hepatology (2013). Epidemiology and natural history of HCV infection. **10**, 553.

Hassan, N., Amin, F., Bashir, K., Irshad, M., Jamil, S., Munawar, N., Haqqani, H., Shabir, H., and Khan, M. (2023). Antiviral response of drugs used against hbv patients of Khyber Pakhtunkhwa, Pakistan. *Bulletin of Biological and Allied Sciences Research* **2023**, 49-49.

Holz, L., and Rehermann, B. J. A. r. (2015). T cell responses in hepatitis C virus infection: historical overview and goals for future research. **114**, 96-105.

Horner, S. M., and Gale, M. J. N. m. (2013). Regulation of hepatic innate immunity by hepatitis C virus. **19**, 879-888.

Huang, H., Sun, F., Owen, D. M., Li, W., Chen, Y., Gale, M., and Ye, J. J. P. o. t. N. A. o. S. (2007). Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. **104**, 5848-5853.

Jimenez, A. P., Eldin, N. S., Rimlinger, F., El-Daly, M., El-Hariri, H., El-Hoseiny, M., Mohsen, A., Mostafa, A., Delarocque-Astagneau, E., and

Abdel-Hamid, M. J. G. (2010). HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. **59**, 1554-1560.

Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., and Sarnow, P. J. s. (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. **309**, 1577-1581.

Karoney, M. J., and Siika, A. M. J. P. A. m. j. (2013). Hepatitis C virus (HCV) infection in Africa: a review. **14**.

Kato, N. J. M., and genomics, c. (2000). Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. **5**, 129-151.

Keating, G. M., and Vaidya, A. J. D. (2014). Sofosbuvir: first global approval. **74**, 273-282.

Kenny-Walsh, E. J. N. E. J. o. M. (1999). Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. **340**, 1228-1233.

Khan, N., Akmal, M., Hayat, M., Umar, M., Ullah, A., Ahmed, I., Rahim, K., Ali, S., Bahadar, S., and Saleha, S. J. H. m. (2014). Geographic distribution of hepatitis C virus genotypes in pakistan. **14**.

Kokudo, N., Takemura, N., Hasegawa, K., Takayama, T., Kubo, S., Shimada, M., Nagano, H., Hatano, E., Izumi, N., and Kaneko, S. J. H. R. (2019). Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. **49**, 1109-1113.

Kramer, J. R., Kowalkowski, M. A., Duan, Z., and Chiao, E. Y. J. J. J. o. A. I. D. S. (2015). The effect of HIV viral control on the incidence of hepatocellular carcinoma in veterans with hepatitis C and HIV coinfection. **68**, 456-462.

Krekulova, L., Řehák, V., and Riley, L. J. F. m. (2006). Structure and functions of hepatitis C virus proteins: 15 years after. **51**, 665-680.

Kruse, R. L., Kramer, J. R., Tyson, G. L., Duan, Z., Chen, L., El-Serag, H. B., and Kanwal, F. J. H. (2014). Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. **60**, 1871-1878.

Lamoury, F. M., Bajis, S., Hajarizadeh, B., Marshall, A. D., Martinello, M., Ivanova, E., Catlett, B., Mowat, Y., Marks, P., and Amin, J. J. T. J. o. i. d. (2018). Evaluation of the Xpert HCV viral load finger-stick point-of-care assay. **217**, 1889-1896.

Laperche, S., and Transfusion, F. A. G. f. R. i. B. T. J. (2013). Multinational assessment of blood-borne virus testing and transfusion safety on the African continent. **53**, 816-826.

Lavanchy, D. J. C. M., and Infection (2011). Evolving epidemiology of hepatitis C virus. **17**, 107-115.

Lok, A. S., Seeff, L. B., Morgan, T. R., Di Bisceglie, A. M., Sterling, R. K., Curto, T. M., Everson, G. T., Lindsay, K. L., Lee, W. M., and Bonkovsky, H. L. J. G. (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. **136**, 138-148.

Lundin, M., Lindström, H., Grönwall, C., and Persson, M. A. J. J. o. g. v. (2006). Dual topology of the processed hepatitis C virus protein NS4B is influenced by the NS5A protein. **87**, 3263-3272.

Maggi, F., Focosi, D., and Pistello, M. J. C. d. t. (2017). How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection? **18**, 811-825.

Magiorkinis, G., Magiorkinis, E., Paraskevis, D., Ho, S. Y., Shapiro, B., Pybus, O. G., Allain, J.-P., and Hatzakis, A. J. P. M. (2009). The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. **6**, e1000198.

Mahale, P., Torres, H. A., Kramer, J. R., Hwang, L. Y., Li, R., Brown, E. L., and Engels, E. A. J. C. (2017). Hepatitis C virus infection and the risk of cancer among elderly US adults: a registry-based case-control study. **123**, 1202-1211.

Mancebo, A., González–Diéguez, M. L., Cadahía, V., Varela, M., Pérez, R., Navascués, C. A., Sotorríos, N. G., Martínez, M., Rodrigo, L., Rodríguez, M. J. C. g., and hepatology (2013). Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. **11**, 95-101.

Marcellin, P. J. L. I. (2009). Hepatitis B and hepatitis C in 2009. **29**, 1-8.

Margraf, R. L., Erali, M., Liew, M., and Wittwer, C. T. J. J. o. c. m. (2004). Genotyping hepatitis C virus by heteroduplex mobility analysis using temperature gradient capillary electrophoresis. **42**, 4545-4551.

McLauchlan, J. J. J. o. v. h. (2000). Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. **7**, 2-14.

Murphy, D. G., Willems, B., Deschênes, M., Hilzenrat, N., Mousseau, R., and Sabbah, S. J. J. o. c. m. (2007). Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5′ untranslated region sequences. **45**, 1102-1112.

Nouroz, F., Shaheen, S., Mujtaba, G., and Noreen, S. J. E. J. o. M. H. G. (2015). An overview on hepatitis C virus genotypes and its control. **16**, 291-298.

Obaid, A., Ahmad, J., Naz, A., Awan, F. M., Paracha, R. Z., Tareen, S. H. K., Anjum, S., Raza, A., Baumbach, J., and Ali, A. J. I. B. (2015). Modeling and analysis of innate immune responses induced by the host cells against hepatitis C virus infection. **7**, 544-559.

Okuda, M., Li, K., Beard, M. R., Showalter, L. A., Scholle, F., Lemon, S. M., and Weinman, S. A. J. G. (2002). Mitochondrial injury, oxidative

stress, and antioxidant gene expression are induced by hepatitis C virus core protein. **122**, 366-375.

Patel, P. R., Larson, A. K., Castel, A. D., Ganova-Raeva, L. M., Myers, R. A., Roup, B. J., Farrell, K. P., Edwards, L., Nainan, O., and Krick, J. P. J. J. (2006). Hepatitis C virus infections from a contaminated radiopharmaceutical used in myocardial perfusion studies. **296**, 2005-2011.

Paul, D., Madan, V., Bartenschlager, R. J. C. h., and microbe (2014). Hepatitis C virus RNA replication and assembly: living on the fat of the land. **16**, 569-579.

Petruzziello, A., Marigliano, S., Loquercio, G., Cozzolino, A., and Cacciapuoti, C. J. W. j. o. g. (2016). Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. **22**, 7824.

Pietschmann, T., Kaul, A., Koutsoudakis, G., Shavinskaya, A., Kallis, S., Steinmann, E., Abid, K., Negro, F., Dreux, M., and Cosset, F.-L. J. P. o. t. N. A. o. S. (2006). Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. **103**, 7408-7413.

Prati, D. J. J. o. h. (2006). Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. **45**, 607-616.

Puchades Renau, L., and Berenguer, M. J. H. I. (2018). Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. **22**, S8-S21.

Quan, V. M., Go, V. F., Nam, L. V., Bergenstrom, A., Thuoc, N. P., Zenilman, J., Latkin, C., and Celentano, D. D. J. A. c. (2009). Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case–control study. **21**, 7-16.

Raja, N. S., Janjua, K. A. J. J. o. M., Immunology,, and Infection (2008). Epidemiology of hepatitis C virus infection in Pakistan. **41**, 4-8.

Rauf, A., Nadeem, M. S., Ali, A., Iqbal, M., Mustafa, M., Muzammal Latif, M., Latif, M. Z., Ahmed, N., and Shakoori, A. R. J. T. E. J. o. P. H. (2011). Prevalence of hepatitis B and C in internally displaced persons of war against terrorism in Swat, Pakistan. **21**, 638-642.

Report, W. H. O. J. S. (2011). Global database on blood safety. **2011**, 3-4.

Roberts, E. A., and Yeung, L. J. H. (2002). Maternal-infant transmission of hepatitis C virus infection. **36**, S106-S113.

Rosa, D., Campagnoli, S., Moretto, C., Guenzi, E., Cousens, L., Chin, M., Dong, C., Weiner, A. J., Lau, J., and Choo, Q.-L. J. P. o. t. N. A. o. S. (1996). A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. **93**, 1759-1763.

Santolini, E., Pacini, L., Fipaldini, C., Migliaccio, G., and Monica, N. J. J. o. v. (1995). The NS2 protein of hepatitis C virus is a transmembrane polypeptide. **69**, 7461-7471.

Scheel, T. K., Gottwein, J. M., Jensen, T. B., Prentoe, J. C., Hoegh, A. M., Alter, H. J., Eugen-Olsen, J., and Bukh, J. J. P. o. t. N. A. o. S. (2008). Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. **105**, 997-1002.

Scheel, T. K., and Rice, C. M. J. N. m. (2013). Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. **19**, 837-849.

Schoggins, J. W., and Rice, C. M. J. H. C. V. F. M. V. t. A. T. (2013). Innate immune responses to hepatitis C virus. 219-242.

Schulze-Krebs, A., Preimel, D., Popov, Y., Bartenschlager, R., Lohmann, V., Pinzani, M., and Schuppan, D. J. G. (2005). Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. **129**, 246-258.

Sheahan, T., Imanaka, N., Marukian, S., Dorner, M., Liu, P., Ploss, A., Rice, C. M. J. C. h., and microbe (2014). Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. **15**, 190-202.

Sheema, Bashir, K., Fiaz, S., Khan, A. W., Haqqani, S., Bibi, A., Nawaz, K., Khan, M. A., and Ullah, A. (2024). Molecular identification of hcv genotypes among injecting drug users having HCV and HIV co-infection. *Bulletin of Biological and Allied Sciences Research* **2024**, 71.

Shekhar, S. (2018). Hepatitis C Virus Infection in the Indian Sub-Continent. *In* "Hepatitis C in Developing Countries", pp. 83-95. Elsevier.

Shimakami, T., Yamane, D., Jangra, R. K., Kempf, B. J., Spaniel, C., Barton, D. J., and Lemon, S. M. J. P. o. t. N. A. o. S. (2012). Stabilization of hepatitis C virus RNA by an Ago2–miR-122 complex. **109**, 941-946.

Sievert, W., Altraif, I., Razavi, H. A., Abdo, A., Ahmed, E. A., AlOmair, A., Amarapurkar, D., Chen, C. H., Dou, X., and El Khayat, H. J. L. i. (2011). A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. **31**, 61-80.

Simmonds, P. J. J. o. G. V. (2004). Genetic diversity and evolution of hepatitis C virus–15 years on. **85**, 3173-3188.

Smith, D. B., Bukh, J., Kuiken, C., Muerhoff, A. S., Rice, C. M., Stapleton, J. T., and Simmonds, P. J. H. (2014). Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. **59**, 318-327.

Stanaway, J. D., Flaxman, A. D., Naghavi, M., Fitzmaurice, C., Vos, T., Abubakar, I., Abu-Raddad, L. J., Assadi, R., Bhala, N., and Cowie, B. J. T. L. (2016). The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. **388**, 1081-1088.

Steinmann, E., Penin, F., Kallis, S., Patel, A. H., Bartenschlager, R., and Pietschmann, T. J. P. P. (2007). Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. **3**, e103.

Strader, D. B., and Seeff, L. B. J. C. L. D. (2012). A brief history of the treatment of viral hepatitis C. **1**, 6-11.

Tagny, C. T., Mbanya, D., Tapko, J. B., and Lefrère, J. J. J. T. (2008). Blood safety in Sub-Saharan Africa: a multi-factorial problem. **48**, 1256-1261.

Te, H. S., Randall, G., Jensen, D. M. J. G., and hepatology (2007). Mechanism of action of ribavirin in the treatment of chronic hepatitis C. **3**, 218.

Terrault, N. A. J. H. (2002). Sexual activity as a risk factor for hepatitis C. **36**, S99-S105.

Thein, H. H., Yi, Q., Dore, G. J., and Krahn, M. D. J. H. (2008). Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. **48**, 418-431.

Thompson, N. D., Perz, J. F., Moorman, A. C., and Holmberg, S. D. J. A. o. I. M. (2009). Nonhospital health care–associated hepatitis B and C virus transmission: United States, 1998–2008. **150**, 33-39.

Tomasetti, C., Li, L., and Vogelstein, B. J. S. (2017). Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. **355**, 1330-1334.

Tong, M. J., El-Farra, N. S., Reikes, A. R., and Co, R. L. J. N. E. J. o. M. (1995). Clinical outcomes after transfusion-associated hepatitis C. **332**, 1463-1466.

Turner, K. M., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., May, M., Taylor, A., De Angelis, D., and Cameron, S. J. A. (2011). The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. **106**, 1978-1988.

Ullah, I., Ullah, A., Rehman, S., Ullah, S., Ullah, H., Haqqni, S., Amir, M., Gul, F., and Bashir, K. (2023). Prevalence and risk factors of helicobacter pylori infection among individuals with tobacco consumption habits in district Peshawar: a cross-sectional study. *Bulletin of Biological and Allied Sciences Research* **2023**, 42-42.

van de Laar, T. J., Matthews, G. V., Prins, M., and Danta, M. J. A. (2010). Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. **24**, 1799-1812.

Velati, C., Romanò, L., Baruffi, L., Pappalettera, M., Carreri, V., and Zanetti, A. R. J. T. (2002). Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. **42**, 989-993.

Vescovo, T., Refolo, G., Vitagliano, G., Fimia, G. M., Piacentini, M. J. C. M., and Infection (2016). Molecular mechanisms of hepatitis C virus–induced hepatocellular carcinoma. **22**, 853-861.

Wang, H., Naghavi, M., Allen, C., Barber, R., Carter, A., Casey, D., Charlson, F., Chen, A., Coates, M., and Coggeshall, M. J. T. L. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â 2015: a systematic analysis for the Global Burden of Disease Study 2015. **388**, 1459-1544.

Wieland, S., Makowska, Z., Campana, B., Calabrese, D., Dill, M. T., Chung, J., Chisari, F. V., and Heim, M. H. J. H. (2014). Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. **59**, 2121-2130.

Wölk, B., Sansonno, D., Kräusslich, H.-G., Dammacco, F., Rice, C. M., Blum, H. E., and Moradpour, D. J. J. o. v. (2000). Subcellular localization, stability, andtrans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. **74**, 2293-2304.

Yamaga, A. K., and Ou, J.-h. J. J. o. B. C. (2002). Membrane topology of the hepatitis C virus NS2 protein. **277**, 33228-33234.

Yang, J. D., and Roberts, L. R. J. I. D. C. (2010). Epidemiology and management of hepatocellular carcinoma. **24**, 899-919.

Zeisel, M. B., Felmlee, D. J., and Baumert, T. F. J. H. C. V. F. M. V. t. A. T. (2013). Hepatitis C virus entry. 87-112.

Declaration

Author contribution statement

All authors contributed equally.

Acknowledgement

Not applicable

Conflict of interest

There is no conflict of interest among the authors.

Data Availability statement

All authenticated data have been included in the manuscript.

Ethics approval and consent to participate

These aspects are not applicable in this paper.

Consent for publication

Not applicable

Funding

There were no sources providing support, for this paper.